These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 17194907)

  • 1. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
    J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
    Copp H; Bissonette EA; Theodorescu D
    Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
    Armstrong JG; Gillham CM; Dunne MT; Fitzpatrick DA; Finn MA; Cannon ME; Taylor JC; O'Shea CM; Buckney SJ; Thirion PG
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):35-45. PubMed ID: 20797824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined modality treatment in the management of high-risk prostate cancer.
    Stock RG; Cahlon O; Cesaretti JA; Kollmeier MA; Stone NN
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1352-9. PubMed ID: 15275720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
    Berthelet E; Pickles T; Lee KW; Liu M; Truong PT;
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.